Glifo-M Tablet 12.5 mg + 500 mg is a combination oral antidiabetic medication containing Empagliflozin (12.5 mg) and Metformin Hydrochloride (500 mg). This combination is designed for the effective management of type 2 diabetes mellitus by targeting blood glucose control through two complementary mechanisms.

• Empagliflozin, an SGLT2 inhibitor, reduces blood glucose by blocking renal glucose reabsorption, promoting glucose excretion in urine.

• Metformin, a biguanide, decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues.

Glifo-M provides enhanced glycemic control for adults who are not achieving optimal blood sugar regulation with monotherapy or lifestyle modifications alone. The combination also offers additional benefits, including weight management and cardiovascular protection.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Glifo-M Tablet 12.5 mg + 500 mg is indicated for:

• Type 2 diabetes mellitus requiring improved glycemic control

• Patients who need dual-action therapy for fasting and postprandial glucose management

• Adjunct therapy in combination with diet and lifestyle changes

• Suitable for patients at high cardiovascular risk, as Empagliflozin has cardiovascular benefits

This combination is not indicated for type 1 diabetes or diabetic ketoacidosis.

Mechanism of Action

• Empagliflozin: Blocks Sodium-Glucose Cotransporter-2 (SGLT2) in the proximal renal tubules, increasing urinary glucose excretion and lowering blood glucose.

• Metformin Hydrochloride: Decreases hepatic gluconeogenesis, enhances insulin sensitivity, and reduces intestinal glucose absorption.

• Complementary action: The combination addresses both insulin-independent and insulin-sensitive pathways, resulting in effective and stable blood glucose control.

• Additional benefits: Promotes weight reduction through glucose excretion and improved metabolic efficiency and offers cardiovascular protection.

Dosage and Administration

• Adults: 1 tablet twice daily with meals to reduce gastrointestinal side effects, or as prescribed by a healthcare professional.

• Monitoring: Regular blood glucose, HbA1c, renal function, and electrolytes are recommended.

• Ensure adequate hydration, particularly when taking Empagliflozin, to prevent dehydration.

• Continue with dietary modifications, regular exercise, and lifestyle management alongside medication.

Benefits and Features

• Dual-action therapy for superior glycemic control

• Reduces fasting and postprandial blood glucose levels

• Supports weight management through insulin-independent glucose excretion

• Provides cardiovascular and renal protective effects

• Convenient twice-daily dosing

• Can be used as part of combination therapy or as monotherapy adjunct

Side Effects

Glifo-M Tablet 12.5 mg + 500 mg is generally well tolerated. Possible side effects include:

• Gastrointestinal disturbances (nausea, diarrhea, or abdominal discomfort)

• Increased urination and mild dehydration due to Empagliflozin

• Genital or urinary tract infections (more common in women)

• Rare hypoglycemia, particularly when combined with other insulin secretagogues

• Rare allergic reactions such as rash or itching

Consult a healthcare professional if severe or persistent side effects occur.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Not suitable for type 1 diabetes or diabetic ketoacidosis

• Use cautiously in patients with renal impairment or dehydration

• Maintain adequate fluid intake to prevent hypotension or dehydration

• Inform your doctor of all medications to avoid drug interactions

• Monitor blood glucose, renal function, and electrolytes regularly

Storage Conditions

Store Glifo-M Tablet 12.5 mg + 500 mg in a cool, dry place below 30°C, away from direct sunlight and moisture. Keep out of reach of children.

Glifo-M Tablet 12.5 mg + 500 mg is a safe and effective combination therapy that provides comprehensive glycemic control, cardiovascular protection, and weight management, making it an ideal choice for adults with type 2 diabetes seeking dual-action diabetes management.